Ozempic pens on a production line at Novo Nordisk facility in Hillerod, Denmark, in 2023.Tom Little/Reuters
Listen to this episode by clicking above or subscribe to The Decibel on your favourite podcast app or platform: Apple Podcasts, Spotify, Amazon Music, iHeartRadio, Pocket Casts and YouTube.
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades.
Today, he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians.
Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s – and a patient who takes them.
This is part of a three-part series. The next episode is next Monday, March 2.
You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website.
Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com